Avidity Biosciences — Investor Day (April 2023)
45 slides from Avidity Biosciences's investor day presentation, Apr 27, 2023
Slide 1: Investor & Analyst Event Series – Volume 7: AOC 1001 MARINA Phase 1/2 Topline Data
1 Investor & Analyst Event Series – Volume 7 AOC 1001 MARINATM Phase 1/2 Topline Data Kristl, Zen & Loraine living with DM1 Nathan living with DMD Josh living with FSHD
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements, including, but not li
Slide 3: Our Vision
3 Our Vision To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Luke Living with DM1
Slide 4: Advancing a New Class of RNA Therapeutics
4 Advancing a New Class of RNA Therapeutics • Progressing robust pipeline in muscle; three programs in clinical development in approximately one year • Leveraging expertise in rare diseases and RNA therapies to execute clinical programs and commercial operations • Building an integrated and diverse
Slide 5: Proof of AOC Platform: AOC 1001 Topline Data
5 Proof of AOC Platform AOC 1001 Topline Data: Disease Modification, Functional Improvement, and Dose Range Identified in DM1 Impact on Disease Mechanism Functional Improvement Safety & Tolerability Completed Successful MARINA Trial *Sept. 2022, FDA placed a partial clinical hold on new participant
Slide 6: Goals for the Day
6 • Share AOC 1001 MARINA topline safety, functional and biomarker data • Discuss Avidity’s disruptive and broad AOC Platform • Answer your questions Goals for the Day mAb OLIGO AOC 1001
Slide 7: AOC 1001 MARINA Phase 1/2 Trial Topline Data Assessment: Management Team
7 7 AOC 1001 MARINATM Phase 1/2 Trial Topline Data Assessment Avidity Management Team Nicholas E. Johnson, M.D. M.Sci., FAAN Virginia Commonwealth University GUEST SPEAKER Art Levin, Ph.D. Distinguished Scientist & Strategic Leader Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President & CEO
Slide 8: Agenda
8 AGENDA Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Michael Flanagan, Ph.D., CSO & CTO Art Levin, Ph.D., Avidity Board Member & Distinguished Scientist & Strategic Leader Sarah Boyce, President & CEO Avidity Managemen
Slide 9: MARINA: A Phase 1/2 Clinical Trial to Evaluate AOC 1001 in Adult Patients with DM1
MARINA: A Phase 1/2 Clinical Trial to Evaluate AOC 1001 in Adult Patients with DM1 Steve Hughes, M.D., Chief Medical Officer
Slide 10: DM1 Burden and Significant Unmet Need
10 0 APPROVED THERAPIES DM1 Burden and Significant Unmet Need >40,000 PEOPLE WITH DM1 IN THE US • Complex disease with symptoms that present with high variability from patient to patient • Monogenic, autosomal dominant, progressive disease that primarily affects muscle: skeletal, cardiac & smooth •
Slide 11: Update on Clinical Trials
11 Update on Clinical Trials • Discussions with FDA on the AOC 1001 partial clinical hold for new participant enrollment remain ongoing • The partial hold is in response to a serious adverse event (SAE) reported in a single participant in the 4mg/kg cohort comprising of bilateral ischemia in the reg
Slide 12: MARINA Trial Designed to Evaluate Safety and Tolerability of AOC 1001
12 *Sept. 2022, FDA placed a partial clinical hold on new participant enrollment. All current participants may continue in their current dosing cohort. Avidity is working to resolve the partial clinical hold as quickly as possible. **Upon entry into MARINA OLE, biopsies were only taken for participa
Slide 13: Preliminary Assessment in December 2022: DM1 Cascade to Functional Benefit
13 Preliminary Assessment in December 2022: DM1 Cascade to Functional Benefit Early responders demonstrated myotonia improvement • 16% splicing improvement across 22 gene panel • 31% improvement in key muscle-specific panel • 100% of treated participants had a DMPK reduction • 45% mean DMPK reductio
Slide 14: AOC 1001 Positive Topline Data Demonstrates Disease Modification and Functional Improvement
14 • Directional improvement in multiple scores on a patient level • Improvements in myotonia & muscle strength and early signs in mobility • Splicing changes followed by functional improvement in 2- 4mg/kg doses • Broad splicing changes in over a thousand genes confirm activity in the nucleus • Del
Slide 15: MARINA Topline Functional Assessments
15 EARLY SIGNS OF IMPROVEMENT IN MOBILITY MEASURES IMPROVEMENT IN MYOTONIA IMPROVEMENT IN STRENGTH MARINA Topline Functional Assessments Timed Up and Go (TUG) Quantitative Muscle Testing (QMT) Total Score* Hand Grip Elbow Extension & Elbow Flexion Knee Extension & Knee Flexion Ankle Dorsiflexion 10
Slide 16: Agenda
16 AGENDA Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Michael Flanagan, Ph.D., CSO & CTO Art Levin, Ph.D., Avidity Board Member & Distinguished Scientist & Strategic Leader Sarah Boyce, President & CEO Avidity Manageme
Slide 17: Topline Data from the AOC 1001 MARINA Phase 1/2 Trial
17 Topline Data from the AOC 1001 MARINA Phase 1/2 Trial Nicholas E. Johnson, M.D., M.Sci., FAAN Associate Professor & Vice Chair of Research, Department of Neurology, Virginia Commonwealth University Dr. Johnson is an associate professor and vice chair of research in the department of neurology at
Slide 18: Topline Data from the AOC 1001 MARINA Phase 1/2 Trial
Topline Data from the AOC 1001 MARINA Phase 1/2 Trial Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University
Slide 19: Baseline Demographics and Disease Characteristics
19 Baseline Demographics and Disease Characteristics * Composite of 22 splicing events; higher number is more severe; 1 participant in the placebo group and 3 participants in the 4mg/kg cohort had insufficient tissue for analysis ◊ As measured by the middle finger opening time † QMT is a total compo
Slide 20: Generally Favorable Safety and Tolerability
20 Generally Favorable Safety and Tolerability Subjects with ≥ 1 AE n (%) Placebo N=10 1 mg/kg N=6 2 mg/kg N=9 4 mg/kg N=13 Any AE 8 (80%) 6 (100%) 9 (100%) 13 (100%) Related to study drug 2 (20%) 1 (17%) 3 (33%) 10 (77%) Serious AE (SAE)* 0 0 1 (11%) 1 (8%) AE leading to study discontinuation** 0 0
Slide 21: AOC 1001 Demonstrates Myotonia Reduction in Early Responder from 2mg/kg Cohort
21 AOC 1001 Demonstrates Myotonia Reduction in Early Responder from 2mg/kg Cohort Improvement visible 3 months following the third dose at 2 mg/kg Participant from 2mg/kg Multidose Baseline vHOT Day 183 vHOT 3 months after third dose vHOT, video hand opening time.
Slide 22: Improvements in Myotonia, a Hallmark of DM1
22 Participants Treated with AOC 1001 Demonstrated Improvements in Myotonia, a Hallmark of DM1 at 2 mg/kg and 4 mg/kg *Measurements for vHOT are based on middle finger opening time. Placebo group combined from Cohort B1 (2mg/kg) and Cohort B2 (4mg/kg) AOC 1001 achieved statistical significance at 4m
Slide 23: Improvements in Total Muscle Strength at 2 mg/kg and 4 mg/kg
23 Participants Treated with AOC 1001 had Improvements in Total Muscle Strength at 2 mg/kg and 4 mg/kg Placebo group combined from Cohort B1 (2mg/kg) and Cohort B2 (4mg/kg) Error bars = standard error of the mean (SEM) †QMT Total Score is based on 6 muscle groups from both upper and lower body ⱡ % p
Slide 24: Early Signs of Improvement in Mobility Measures (10mWRT)
24 AOC 1001 Showed Early Signs of Improvement in Mobility Measures -1.0 -0.5 0.0 0.5 Days Ch an ge fr om B as el in e (s ec ) Placebo 2 mg/kg 4 mg/kg Dosing D43 D92D1 10 Meter Walk Run Test (10mWRT) Im pr ov em en t D183 EARLY SIGNS OF IMPROVEMENT IN MOBILITY MEASURES 10 Meter Walk Run Test (10mWRT)
Slide 25: Early Signs of Improvement in Mobility Measures (TUG)
25 EARLY SIGNS OF IMPROVEMENT IN MOBILITY MEASURES -0.5 0.0 0.5 Days Ch an ge fr om B as el in e (s ec ) Placebo 2 mg/kg 4 mg/kg Dosing D92D1 D43 AOC 1001 Showed Early Signs of Improvement in Mobility Measures Timed Up and Go (TUG) Im pr ov em en t D183 Timed Up and Go (TUG)
Slide 26: AOC 1001 Demonstrates Myotonia Reduction in 4 mg/kg Cohort
26 AOC 1001 Demonstrates Myotonia Reduction in 4 mg/kg Cohort Baseline vHOT Day 183 vHOT Improvement visible 3 months following the third dose at 4 mg/kg vHOT, video hand opening time. ` Participant from 4 mg/kg Multidose
Slide 27: MARINA Demonstrates AOC 1001 Impacts Disease Mechanism and Achieves Functional Improvement
27 MARINA Phase 1/2 Trial Demonstrates AOC 1001 Impacts Disease Mechanism and Achieves Functional Improvement • DM1 is an underrecognized, progressive, and often fatal neuromuscular disease with a high unmet need and no approved therapies • AOC 1001 is an investigational antibody oligonucleotide con
Slide 28: Agenda
28 AGENDA Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Michael Flanagan, Ph.D., CSO & CTO Art Levin, Ph.D., Avidity Board Member & Distinguished Scientist & Strategic Leader Sarah Boyce, President & CEO Avidity Manageme
Slide 29: AOC 1001: Impact on Disease Mechanism
AOC 1001: Impact on Disease Mechanism W. Michael Flanagan Chief Scientific and Technical Officer
Slide 30: AOC 1001 Positive Topline Data Demonstrates Disease Modification and Functional Improvement
30 • Directional improvement in multiple scores on a patient level • Improvements in myotonia & muscle strength and early signs in mobility • Splicing changes followed by functional improvement in 2- 4mg/kg doses • Broad splicing changes in over a thousand genes confirm activity in the nucleus • Del
Slide 31: MARINA Topline Data at Weeks Post-Dose
31 MARINA™ Topline Data at 6 Weeks Post-Dose Dose BoosterBiopsy - 1 participant in 2 mg/kg group had a muscle biopsy soon after the third dose and was removed from the PK analysis - 1 participant in the placebo group, 1 from the 1mg/kg and 3 participants in the 4mg/kg cohort had insufficient tissue
Slide 32: AOC 1001 Delivered siRNA to Muscle
32 AOC 1001 Delivered siRNA to Muscle Expanding siRNA Therapeutics Beyond Liver Dose Proportional Increase in Muscle siRNA Concentrations 1 2 4 Dose (mg/kg) si R N A in M us cl e (n M ) 6 w ee ks a fte r d os e 1 dose q6W x 2 q6W x 2 PROOF OF AOC PLATFORM FUNCTIONAL IMPROVEMENT IMPACT ON DISEASE MEC
Slide 33: AOC 1001 Produced 42% Mean DMPK Knockdown
33 AOC 1001 Produced 42% mean DMPK Knockdown Demonstrating Target Engagement DMPK Reduction Across all Cohorts Placebo group combined from both cohorts and shown as standard error of mean Data shown at 6 weeks post a single dose of 1mg/kg or two doses of 2 or 4 mg/kg 1mg/kg (n=5) 2mg/kg (n=9) Placeb
Slide 34: Splicing Improvements in 22 Gene Panel
34 Sp lic e In de x (c ha ng e fro m b as el in e) Splicing Improvements in 22 Gene Panel Demonstrates AOC 1001 is Impacting DM1 Disease Mechanism Splicing measured by targeted RNA sequencing and calculated using published formula (Tanner et. al 2021) Splicing Index for each participant is calculate
Slide 35: Muscle-Specific Biomarkers Show Splicing Improvement
35 Muscle-Specific Biomarkers Show Splicing Improvement 4-Gene Muscle Splicing Panel for Individual Patients and Cohorts Data shown at 6 weeks post a single dose of the 1mg/kg and 6 weeks post two doses of 2mg/kg or 4 mg/kg Sp lic in g im pr ov em en t Muscle panel: CLCN1, CACNA1S, ATP2A1, BIN1 1mg/
Slide 36: AOC 1001 Broadly Impacts DM1 Disease Mechanism in Over 1,000 Splicing Events
AOC 1001 (2 mg/kg) Broadly Impacts DM1 Disease Mechanism in Over 1,000 Splicing Events Responsive to mutant DMPK mRNA reduction Specific to muscle Biological relevance to disease RNA sequencing utilized to identify mis-spliced mRNA transcripts changed (p <0.05, mean PSI difference > 5) at 6 weeks po
Slide 37: Delivering on the AOC Platform and Impacting Disease Mechanism
37 Delivering on the AOC Platform and Impacting Disease Mechanism Platform Achievements: • AOC technology delivered siRNA to muscle – a first for the RNA field • AOC 1001 achieved DMPK knockdown demonstrating target engagement • 42% mean DMPK reduction in treated participants DM1 Advancements: • Dem
Slide 38: Agenda
38 AGENDA Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Michael Flanagan, Ph.D., CSO & CTO Art Levin, Ph.D., Avidity Board Member & Distinguished Scientist & Strategic Leader Sarah Boyce, President & CEO Avidity Manageme
Slide 39: Delivering on the AOC Platform - Broad Utility & Power of the Platform
Delivering on the AOC Platform - Broad Utility & Power of the Platform Art Levin, Avidity Board Member and Distinguished Scientist & Strategic Leader
Slide 40: AOC Platform: Building on the Power of Oligonucleotides
40 AOC™ Platform: Building on the Power of Oligonucleotides AOC platform advantages include: MONOCLONAL ANTIBODIES mAb OLIGO Designed to combine the specificity of mAbs with the precision of oligonucleotide therapies OLIGONUCLEOTIDE THERAPIES OLIGOmAb ANTIBODY OLIGONUCLEOTIDE CONJUGATE (AOC) Abili
Slide 41: Diverse and Expanding AOC Pipeline
41 Diverse and Expanding AOC Pipeline PROGRAM / INDICATION TARGET LEAD OPTIMIZATION IND ENABLING PHASE 1/2 PHASE 3 AOC 1001 Myotonic Dystrophy Type 1 (DM1) DMPK AOC 1044 Duchenne Muscular Dystrophy (DMD) Exon 44 AOC 1020 Facioscapulohumeral Muscular Dystrophy (FSHD) DUX4 Additional DMD Programs Exon
Slide 42: A New Paradigm of RNA Therapeutics with AOCs
42 A New Paradigm of RNA Therapeutics with AOCs AOC mAb OLIGO Past 30 Years 2021 First AOC Dosed in Humans Today AOCs deliver RNA into Skeletal Muscle CARDIAC IMMUNOLOGY OTHER INDICATIONS 2023 and Beyond RNA Therapeutics Focused on delivery to the liver or local delivery Targeting muscle and other t
Slide 43: Agenda
43 AGENDA Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Michael Flanagan, Ph.D., CSO & CTO Art Levin, Ph.D., Avidity Board Member & Distinguished Scientist & Strategic Leader Sarah Boyce, President & CEO Avidity Manageme
Slide 44: Our Vision
44 Our Vision To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Luke Living with DM1
Slide 45: Agenda
45 AGENDA Sarah Boyce, President & CEO Steve Hughes, M.D., CMO Nicholas E. Johnson, M.D., M.Sci., FAAN Virginia Commonwealth University Michael Flanagan, Ph.D., CSO & CTO Art Levin, Ph.D., Avidity Board Member & Distinguished Scientist & Strategic Leader Sarah Boyce, President & CEO Avidity Manageme